Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term clinical assessment of salmeterol + fluticasone (HFA MDI) in pediatric asthma
2015-004881-27Phase 3
- Sponsor
- GSK
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of salmeterol and fluticasone propionate in asthma, sponsored by GSK. Primary endpoint: Primary safety and efficacy assessment.
02
Drugs
salmeterolfluticasone propionate
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-004881-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004881-27.